Thomas is a passionate and innovative technologist with expertise in early-stage technology development and commercialization. He has held several C-level and senior management positions and demonstrated turn-around and team building capability across multiple disciplines.

Thomas is experienced in evaluating technology concepts and developing specific implementation plans from broad strategic goals and concepts. In addition, he has participated in private and public fundraising. His areas of expertise with unique combination of biology, genomics and engineering includes industrial and subsurface applied microbiology and biotechnology.

Thomas has a Master's degree in Chemical Engineering and a PhD in Biotechnology from the Technical University of Denmark and has worked as a visiting researcher at UCLA from 1999-2001. He worked as a Scientist first at TIGR and JCVI in Rockville and La Jolla and later at Synthetic Genomics Inc. where he held positions as Director of Microbial Genomics and Vice President of Product and Technology Development. As Chief Technology Officer, he has developed two technologies to commercial stage, first at Glori Energy Inc. (IPO exit) and Biota Technology Inc. (asset acquisition by Novozymes).

Patents

Systems and methods of microbial enhanced oil recovery (meor) including water …
WO US CN AR BR CA GB MX RU CA2831591C Thomas Ishoey Glori Energy Inc.
Priority 2011-04-12 • Filed 2012-02-15 • Granted 2016-11-08 • Published 2016-11-08

Optimizing enhanced oil recovery by the use of oil tracers
WO US AR US20140124196A1 Thomas Ishoey Glori Energy Inc.
Priority 2012-04-13 • Filed 2013-03-14 • Published 2014-05-08

Amplification of single viral genomes
US US20100047768A1 Thomas Ishoey J. Craig Venter Institute, Inc.
Priority 2008-08-18 • Filed 2009-08-18 • Published 2010-02-25

Microbial enhanced oil recovery delivery systems and methods
WO US AR US8783345B2 Thomas Ishoey Glori Energy Inc.
Priority 2011-06-22 • Filed 2011-06-22 • Granted 2014-07-22 • Published 2014-07-22

Estimating a quantity of molecules in a sample
WO WO2020263921A1 Thomas Ishoey Biota Technology, Inc.
Priority 2019-06-28 • Filed 2020-06-24 • Published 2020-12-30

Research Priorities

Development of Microbiome Rejuvenation Therapy (MRT) platform to enable orally delivered live biotherapeutic products (LBPs) for human diseases. Target indications include Clostridium difficile infection (CDI), antibiotic and cancer treatment and inflammation indications related to microbiome dysbiosis.

MRT platform components include:

  • Data Science and Engineering to define product candidates for target indications and cohorts
  • Isolate, characterize and produce biomass for formulation of product candidate strains
  • Translational science to validate product candidates and enable regulatory path to commercialization 

Publications

Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study.
Nutrients. 2020-07-09; 12.7:
PMID: 32660025
Genomic features of "Candidatus Venteria ishoeyi", a new sulfur-oxidizing macrobacterium from the Humboldt Sulfuretum off Chile.
PloS one. 2017-12-13; 12.12: e0188371.
PMID: 29236755
Isolation and genome analysis of single virions using 'single virus genomics'.
Journal of visualized experiments : JoVE. 2013-05-26; 75: e3899.
PMID: 23728084
Single cell genome amplification accelerates identification of the apratoxin biosynthetic pathway from a complex microbial assemblage.
PloS one. 2011-04-12; 6.4: e18565.
PMID: 21533272
Single virus genomics: a new tool for virus discovery.
PloS one. 2011-03-23; 6.3: e17722.
PMID: 21436882
Targeted metagenomics and ecology of globally important uncultured eukaryotic phytoplankton.
Proceedings of the National Academy of Sciences of the United States of America. 2010-08-17; 107.33: 14679-84.
PMID: 20668244
Genomic sequencing of single microbial cells from environmental samples.
Current opinion in microbiology. 2008-06-10; 11.3: 198-204.
PMID: 18550420
Nanoliter reactors improve multiple displacement amplification of genomes from single cells.
PLoS genetics. 2007-09-01; 3.9: 1702-8.
PMID: 17892324

Research Priorities

Development of Microbiome Rejuvenation Therapy (MRT) platform to enable orally delivered live biotherapeutic products (LBPs) for human diseases. Target indications include Clostridium difficile infection (CDI), antibiotic and cancer treatment and inflammation indications related to microbiome dysbiosis.

MRT platform components include:

  • Data Science and Engineering to define product candidates for target indications and cohorts
  • Isolate, characterize and produce biomass for formulation of product candidate strains
  • Translational science to validate product candidates and enable regulatory path to commercialization